AbbVie's 24% Skyrizi Growth Isn't the Story-Lower Guidance Is

Expectations were already stretched before the report

Last year, AbbVie gave investors a reason to get excited. Reuters reported Skyrizi growing 32.5%, Skyrizi sales reached $5.01 billion, and the company guided 2026 profit above Wall Street estimates. That helped create a market mindset that AbbVie's immunology engine could keep delivering outsized upside.

When a stock gets trained that way, "good" is not always enough. AbbVie posted revenue of $16.99 billion versus $16.77 billion consensus, but it also reported adjusted EPS of $3.65 against $3.71 estimates. The stock responded with a 4.7% premarket drop. In other words, the market had priced in another beat-and-raise moment, and this quarter did not quite clear that bar.

The bigger issue was full-year guidance. AbbVie trimmed its 2026 adjusted EPS range to $13.87 to $14.07 from $13.91 to $14.11, putting the midpoint at $13.97 versus $14.12 consensus. Even with Skyrizi and Rinvoq still growing strongly, that was not enough for investors looking for another surprise quarter.

Skyrizi growth was solid, but the market focused on the guide cut

The operating engine is still working

AbbVie's post-Humira transition is still producing real growth. The company reported 9.5 percent on an operational basis revenue growth, while its immunology portfolio remained the clear driver of momentum. That matters because the core business is not stalling.

But AbbVie had also raised the bar. After management raised its full-year adjusted earnings forecast following first-quarter results, investors entered this quarter expecting another large upside surprise. Instead, the immunology and inflammation portfolio beat consensus by about 1%. That is still execution, just not the kind of blowout number the stock had become accustomed to.

Why bulls and bears are reading the same quarter differently

Bulls can argue the underlying business is healthy and that the guide cut looks tougher than the operating engine: - Revenue is still expanding at a strong pace for a company of AbbVie's size. - The updated EPS range includes a $0.14 per share dilutive impact from the Apogee deal, and William Blair said that four-cent trim may be misinterpreted because it is tied to acquisition accounting. - If investors separate deal-related EPS drag from operating performance, the selloff may look more like overreaction than a fundamental break.

Bears have a simpler read: - A company that was being treated like a growth compounder can still get hit when growth merely looks solid instead of exceptional. - Lower full-year guidance suggests less cushion into next year, even if the quarter itself was decent. - Reuters noted AbbVie trimmed the forecast to account for its planned Apogee Therapeutics acquisition, but the headline still signaled softer near-term profit expectations.

Guidance mattered more than the revenue beat

What the market was repricing was not yesterday's sales. It was tomorrow's earnings power.

AbbVie taking its 2026 adjusted EPS range from $13.91 to $14.11 down to $13.87 to $14.07 was the clearest negative signal in the release. The updated outlook also includes a $0.58 per share unfavorable impact from acquired IPR&D and milestones expense. Bulls will argue that much of the guide cut is accounting noise rather than a sign of weaker demand. Bears will argue that investors do not have to make that distinction right away; a lower annual guide is enough to pressure the multiple.

What the next update needs to show

The selloff only starts to look temporary if management can separate short-term EPS headwinds from the core operating trend. The next report or commentary needs to do three things clearly:

• Explain the Apogee-related dilutive impact and acquired IPR&D and milestones expense so investors can separate them from the underlying business.
• Show that the revenue mix is still tracking in a way that supports the full-year setup.
• Frame Apogee as pipeline expansion to bolster its treatment pipeline, not just another large deal added to the story.

If that happens, the stock may start trading on AbbVie's operating momentum again. If not, the market may keep focusing on guidance and keep the shares in a tighter valuation band.